Therapeutic efficacy of chitosan nanoparticles and albendazole in intestinal murine trichinellosis

Most of the drugs used for the treatment of trichinellosis showed a limited bioavailability and a high degree of resistance. Therefore, there is an urgent need to develop new agents to improve the bioavailability of these drugs. This work assessed the use Chitosan (CH) nanoparticles singly or combined with albendazole (ABZ) for the treatment of experimental trichinellosis. Fifty male albino mice were used. They were divided into six experimental groups. Chitosan nanoparticles were used orally at a dose of 100mg/kg/day starting from 3rd dpi for three successive days for the treatment of the intestinal phase of infection either alone or loaded with full dose or half dose of ABZ. Results showed significant reduction in all treated groups with the highest reduction rate of adult 99.1%, improvement of the intestinal histopathological changes and a significant decrease in iNOS expression of the intestinal tissue were observed in groups treated by CH loaded with full dose of ABZ compared to control group